Home ›
Multiple Myeloma Trials ›
NCT06235229
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
This study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.
Trial Details
NCT ID NCT06235229
Phase PHASE1 / PHASE2
Sponsor Gracell Biotechnologies (Shanghai) Co., Ltd.
Status RECRUITING
Cancer Type Multiple Myeloma
Interventions
Locations (sample) Beijing, China|39.9075,116.39723 Beijing, China|39.9075,116.39723 Hangzhou, China|30.29365,120.16142 Jinan, China|36.66833,116.99722 Shanghai, China|31.22222,121.45806
Key Eligibility Criteria
Patients must have a diagnosis of active multiple myeloma as defined by the updated IMWG (International Myeloma Working Group) criteria, and meet o… Serum M protein ≥ 1 g/dL; Urine M protein ≥ 200 mg/24hrs; Serum free light chain (sFLC) ≥ 10 mg/dL with abnormal sFLC κ/λ ratio.
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Multiple Myeloma Trials on Trialify →